Last updated on November 2017

Focal Segmental Glomerulosclerosis

Brief description of study

Focal Segmental Glomerulosclerosis

Detailed Study Description

In this study Retrophin is studying an investigational drug called Sparsentan for treatment of patients with FSGS. The trial is being conducted to collect information about the possible effects of Sparsentan to treat protein loss in patients with FSGS, as well as other positive and negative effects of the medication.

Clinical Study Identifier: TX7554

Contact Investigators or Research Sites near you

Start Over

Stephanie Hanzl

Northeast Clinical Research Center, LLC.
Bethlehem, PA USA